Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

13.59
+1.199.60%
Post-market: 13.840.2500+1.84%19:58 EDT
Volume:5.38M
Turnover:72.82M
Market Cap:1.21B
PE:-4.04
High:13.90
Open:13.59
Low:12.85
Close:12.40
52wk High:13.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:1.79
T/O Rate:7.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:24.91
PE(LYR):-4.28

Loading ...

Earnings Flash (KURA) Kura Oncology Posts Q2 Loss Per Share $0.77, vs. FactSet Est of Loss $0.88

MT Newswires Live
·
Aug 13

Kura Oncology Q2 Product Revenue Rises 57% on Komzifti Uptake

Reuters
·
Aug 13

Kura Oncology 2Q FY26 Net Loss Widens to $68.3 Million; Revenue Rises to $20.87 Million

Reuters
·
Aug 13

Kura Oncology Q2 EPS $(0.77) Beats $(0.87) Estimate, Sales $20.874M Miss $21.420M Estimate

Benzinga Earnings
·
Aug 13

Kura Oncology Q2 Operating Expenses USD 93.884 Million

Reuters
·
Aug 13

Kura Oncology Q2 Net Income USD -68.327 Million

THOMSON REUTERS
·
Aug 13

Kura Oncology, Inc. Expected to Post a Loss of 88 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Kura Oncology Highlights Ziftomenib Preclinical Activity, Menin Binding Profile in Blood Publication

Reuters
·
Aug 10

Kura Oncology Grants Inducement Stock Options for 104,500 Shares at $9.19 Each

Reuters
·
Aug 07

Kura Oncology Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 07

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 07

Kura Oncology to Report Second Quarter Financial Results

GlobeNewswire
·
Aug 05

Kura Oncology Updates CEO Troy Wilson Severance Terms in Revised Employment Agreement

Reuters
·
Jul 30

Wedbush Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Jul 28

Kura Oncology Price Target Maintained with a $36.00/Share by Wedbush

Dow Jones
·
Jul 28

Charles Zhu Maintains Buy Rating on Kura Oncology, Reiterates $28 Price Target on Encouraging Darlifarnib Combination Data

TIPRANKS
·
Jul 28

Kura Oncology announces durable activity of darlifarnib combination in ccRCC

TIPRANKS
·
Jul 27

Kura Oncology Reports up to 50% Response Rate for Darlifarnib-cabozantinib Combo in Phase 1a Kidney Cancer Trial

Reuters
·
Jul 27

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-NaÏVe Clear Cell Renal Cell Carcinoma Patients at Kcrs 2026

THOMSON REUTERS
·
Jul 27

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

GlobeNewswire
·
Jul 27